Antihypertensives/diuretics and skin cancer

Study type

• Study topic:
  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Assessment of risk minimisation measure implementation or effectiveness
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Systematic review and meta-analysis

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (C09DX01) valsartan, amlodipine and hydrochlorothiazide

  valsartan, amlodipine and hydrochlorothiazide

  (C09BX03) ramipril, amlodipine and hydrochlorothiazide

  ramipril, amlodipine and hydrochlorothiazide

  (C09DX03) olmesartan medoxomil, amlodipine and hydrochlorothiazide

  olmesartan medoxomil, amlodipine and hydrochlorothiazide

  (C03AX01) hydrochlorothiazide, combinations

  hydrochlorothiazide, combinations

  (C03EA01) hydrochlorothiazide and potassium-sparing agents

  hydrochlorothiazide and potassium-sparing agents

  (C03AB03) hydrochlorothiazide and potassium

  hydrochlorothiazide and potassium

  (C03AA03) hydrochlorothiazide

  hydrochlorothiazide

  (C09XA54) aliskiren, amlodipine and hydrochlorothiazide

  aliskiren, amlodipine and hydrochlorothiazide

  (C09XA52) aliskiren and hydrochlorothiazide

  aliskiren and hydrochlorothiazide

Population studied

• Short description of the study population:
  The study focused on association between hydrochlorothiazide/anti-hypertensive drugs and non-melanoma skin cancer/malignant melanoma identified from the existing available evidence.
• Age groups:
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Estimated number of subjects:
  50000

Study design details

• Main study objective:
  This report aims to provide a review of existing available evidence regarding the association between HCTZ/ anti-hypertensive drugs and NMSC/MM, together with a quality appraisal of the existing studies.
• Outcomes:
  malignant melanoma, non-melanoma skin cancer
• Data analysis plan:
  To describe the type of studies, their characteristics and the variables used for confounding adjustment by them.